{
    "clinical_study": {
        "@rank": "161304", 
        "acronym": "BG", 
        "arm_group": [
            {
                "arm_group_label": "Beta-glucan", 
                "arm_group_type": "Experimental", 
                "description": "Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300\u00ae produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300\u00ae, daily, for seven days."
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test wether orally administered Beta-glucan has systemic\n      effects in humans."
        }, 
        "brief_title": "Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Immunologic Deficiency Syndromes", 
        "condition_browse": {
            "mesh_term": "Immunologic Deficiency Syndromes"
        }, 
        "detailed_description": {
            "textblock": "The immunostimulatory properties of mushrooms have been recognized for centuries, and\n      \"medicinal\" mushrooms are still widely used in alternative medicine all over the world.\n      Although a number of fungal components have been implicated in these properties,\n      Beta-glucans have attracted the most attention. However, although Beta-glucans are widely\n      used as a health food supplement, their immunomodulatory effects after administration in\n      humans have not yet been determined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Age \u226518\n\n          -  Healthy males\n\n        Exclusion Criteria:\n\n          -  Subjects with a history of allergy or intolerance to Beta-glucan\n\n          -  Use of any medication\n\n          -  Participation in a drug trial or donation of blood 3 months prior to Beta-glucan\n             administration\n\n          -  Use of antibiotics, norit, laxatives (up till 6 months prior to inclusion),\n             cholestyramine, acid burn inhibitors or immune suppressive agents (up till 3 months\n             prior to inclusion), and pre- and probiotics (up till 1 month prior to inclusion)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "36 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01727895", 
            "org_study_id": "Betaglucan_immunity"
        }, 
        "intervention": {
            "arm_group_label": "Beta-glucan", 
            "intervention_name": "Beta-glucan (Glucan #300\u00ae)", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Betaglucan, immune modulation, immunoparalysis, immune suppression", 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands", 
                    "zip": "6500 HB"
                }, 
                "name": "Radboud University Nijmegen Medical Centre"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans, a Pilot Study", 
        "overall_official": {
            "affiliation": "Radboud University Nijmegen Medical Centre, The Netherlands", 
            "last_name": "Mihai Netea, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the study is to evaluate the systemic effects of orally administered Beta-glucan on innate immune responses of leukocytes. The effects of Beta-glucan will be determined by measuring the ex vivo responsiveness of leukocytes to various inflammatory stimuli as a surrogate marker of the antimicrobial response", 
            "measure": "Tumor necrosis factor (TNF)-\u03b1 secretion by ex vivo lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs)", 
            "safety_issue": "No", 
            "time_frame": "up to  21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01727895"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "\u2022 production of other cytokines (TNF-\u03b1, interleukin (IL)-6, IL-10, IL-1\u03b2, IL-17, IL-22, Interferon (IFN)-\u03b3) by leukocytes ex vivo stimulated with various stimuli (including LPS, Pam3Cys, Mycobacterium tuberculosis, Poly(I:C), Candida, staph aureus)", 
                "safety_issue": "No", 
                "time_frame": "days 0, 6, 21"
            }, 
            {
                "measure": "\u2022 the absorbance of orally administered Beta-glucan into the blood compartment, measured by ELISA", 
                "safety_issue": "No", 
                "time_frame": "Days 0, 6, 21"
            }, 
            {
                "measure": "\u2022 transcriptional pathways (by use of microarrays) with focus on inflammatory pathways.", 
                "safety_issue": "No", 
                "time_frame": "Days 0, 6, 21"
            }, 
            {
                "measure": "\u2022 changes in phenotype and gene expression caused by mechanisms other than changes in the underlying DNA sequence (epigenetic modifications)", 
                "safety_issue": "No", 
                "time_frame": "Days 0, 6, 21"
            }, 
            {
                "measure": "\u2022 the leukocyte capacity to phagocytose and kill the fungal pathogen Candida albicans (antifungal activity).", 
                "safety_issue": "No", 
                "time_frame": "Days 0, 6, 21"
            }, 
            {
                "measure": "the composition of faecal microbiota", 
                "safety_issue": "No", 
                "time_frame": "Days 0, 6, 21"
            }
        ], 
        "source": "Radboud University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}